NasdaqGS:PGENBiotechs
Precigen (PGEN) Is Down 5.7% After Consensus Backs PAPZIMEOS As New First-Line RRP Therapy
In January 2026, Precigen, Inc. reported that an independent expert consensus paper in The Laryngoscope recommended its FDA-approved HPV-specific immunotherapy PAPZIMEOS (zopapogene imadenovec) as the new first-line standard of care for adults with recurrent respiratory papillomatosis, shifting focus from repeated surgery to treating the underlying infection.
Because the paper was sponsored by the Recurrent Respiratory Papillomatosis Foundation and shaped with input from patients and...